1. Home
  2. JYNT vs LUNG Comparison

JYNT vs LUNG Comparison

Compare JYNT & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo The Joint Corp.

JYNT

The Joint Corp.

HOLD

Current Price

$8.42

Market Cap

118.2M

Sector

Miscellaneous

ML Signal

HOLD

Logo Pulmonx Corporation

LUNG

Pulmonx Corporation

N/A

Current Price

$2.41

Market Cap

97.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
JYNT
LUNG
Founded
2010
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Multi-Sector Companies
Industrial Specialties
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
118.2M
97.1M
IPO Year
2014
2020

Fundamental Metrics

Financial Performance
Metric
JYNT
LUNG
Price
$8.42
$2.41
Analyst Decision
Strong Buy
Buy
Analyst Count
2
7
Target Price
$17.00
$5.38
AVG Volume (30 Days)
61.1K
894.6K
Earning Date
05-07-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
133.93
7.64
EPS
0.14
N/A
Revenue
$117,696,356.00
$90,497,000.00
Revenue This Year
$12.23
$2.48
Revenue Next Year
N/A
$18.46
P/E Ratio
$60.07
N/A
Revenue Growth
15.49
8.01
52 Week Low
$7.50
$1.13
52 Week High
$10.74
$2.89

Technical Indicators

Market Signals
Indicator
JYNT
LUNG
Relative Strength Index (RSI) 49.02 66.26
Support Level $8.07 $1.27
Resistance Level $9.49 $2.66
Average True Range (ATR) 0.27 0.18
MACD 0.02 -0.00
Stochastic Oscillator 43.75 68.87

Price Performance

Historical Comparison
JYNT
LUNG

About JYNT The Joint Corp.

The Joint Corp develops, owns, operates, supports, and manages chiropractic clinics through direct ownership, management arrangements, franchising, and the sales of regional developer rights throughout the United States. The doctors of chiropractic develop personalized treatment plans to relieve patients' pain and deliver ongoing preventative care. The company has one operating business segment; The Franchise Operations segment, which is comprised of the operating activities of the franchise business unit. The Franchise Operations segment derives revenue from customers by providing access to the company's franchise license, which represents symbolic intellectual property.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.

Share on Social Networks: